Edition:
United States

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner


Thursday, 19 Jul 2018 01:15am EDT 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.